Clinical Scenario - De Novo HER2-Positive Metastatic Breast Cancer

Dr. Kruse presents approach to a 54-year-old patient with de novo HER2-positive, hormone receptor-positive metastatic breast cancer involving visceral organs and asymptomatic brain metastases. The patient maintains good performance status with minimal comorbidities and prioritizes quality of life and independence.

She emphasizes that uncontrolled cancer represents the greatest threat to quality of life, making aggressive disease control the priority despite treatment-related toxicities. Visceral involvement and brain metastases support T-DXd plus pertuzumab selection, given the regimen's superior CNS activity and overall efficacy.

Communication strategies involve contextualizing toxicity discussions within cancer control benefits, preventing patients from focusing solely on treatment side effects while minimizing cancer-related complications. Liver involvement particularly threatens quality of life through obstruction, fullness, or malignant ascites.

Dr. Rao concurs with T-DXd plus pertuzumab selection, noting that asymptomatic brain metastases might warrant systemic therapy observation before radiation, depending on radiation oncology consultation. The combination's proven CNS activity supports this approach.

The hormone receptor-positive aspect creates additional complexity regarding endocrine therapy integration and potential PATINA trial applications. The panel discusses evolving perspectives on induction therapy followed by maintenance regimens versus continuous combination therapy.

Assessment timing becomes crucial, with data suggesting complete responses may require 8 months and deepest responses up to 24 months. This timeline influences decisions about treatment modifications and sequencing to alternative regimens.

The depth of response may guide subsequent treatment decisions, with deep partial responses or complete responses potentially warranting continued combination therapy, while standard partial responses might benefit from transition to endocrine-based approaches like those studied in PATINA.ecur despite intensive early treatment.